Log in to your Inderes Free account to see all free content on this page.

Qlife Holding

1.98 SEK

-0.25 %

Less than 1K followers

QLIFE

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-0.25 %

-0.75 %

-29.94 %

-29.94 %

-28.43 %

-39.71 %

-98.42 %

-99.98 %

-99.92 %

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. The first capsules in the company's product, Egoo.Health Platform, were CE-marked for professional use in early 2020. The company has patent protection for key parts of its technology. The Danish-based company is listed on Nasdaq First North Stockholm.

Market cap

57.03M SEK

Turnover

110.6 SEK

Revenue

EBIT %

P/E

Dividend yield-%

Coverage

Latest research

Latest analysis report

Released: 07.12.2023

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

13.5.

2026

Interim report Q1'26

27.5.

2026

General meeting '26

26.8.

2026

Interim report Q2'26

All

Research

Webcasts

Press releases

ShowingAll content types

Regulatory press release3/24/2026, 7:30 AM

Qlife Holding AB: Qlife announces the outcome of the rights issue and resolves on a directed issue of shares to guarantors

Press release3/17/2026, 8:00 AM

Qlife Holding AB: Qlife provides business update on clinical progress, partnerships and commercialization initiatives

Regulatory press release3/17/2026, 7:45 AM

Qlife Holding AB: The subscription period in Qlife's rights issue ends on Thursday, 19 March 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release3/13/2026, 7:30 AM

Qlife Holding AB: Hipro to accelerate Egoo development and regulatory approval in China following strong interest

Regulatory press release3/5/2026, 7:50 AM

Qlife Holding AB: The subscription period in Qlife's rights issue begins today

Regulatory press release3/4/2026, 7:40 AM

Qlife Holding AB: Qlife publishes information document due to upcoming rights issue

Regulatory press release2/27/2026, 5:20 PM

Qlife Holding AB: Qlife announces that two investors have entered agreements to subscribe for shares if the rights issue is subscribed below approx. 51.0 percent, taking over commitments from a group of guarantors

Regulatory press release2/26/2026, 10:05 AM

Bulletin from Extraordinary General Meeting 2026 of Qlife Holding AB

Press release2/25/2026, 7:30 AM

Qlife Holding AB: Qlife launches pharmacy pilot project in Nordic markets

Regulatory press release2/19/2026, 5:03 PM

Qlife Holding AB: Guarantor converts guarantee commitment of SEK 0.5 million into binding subscription commitment and top guarantor waives guarantee compensation in Qlife's ongoing rights issue

Regulatory press release2/11/2026, 7:30 AM

Qlife Holding AB: QLIFE HOLDING AB, Interim Report Q4, October - December 2025

Regulatory press release1/26/2026, 9:56 AM

Notice of Extraordinary General Meeting 2026 in Qlife Holding AB

Regulatory press release1/26/2026, 7:30 AM

Qlife Holding AB: Qlife submits Egoo PHE home testing system for regulatory approval

Regulatory press release1/22/2026, 7:50 PM

Qlife Holding AB: Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

Press release1/19/2026, 7:30 AM

Qlife Holding AB: Qlife prepares for pharmacy testing in Nordic markets

Press release1/15/2026, 7:30 AM

Qlife Holding AB: Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships

Press release12/23/2025, 7:30 AM

Qlife Holding AB: Qlife provides end-year operational update on key issues

Regulatory press release12/16/2025, 7:31 AM

Qlife Holding AB: Qlife and Hipro sign exclusive commercial agreement covering Qlife's sale of Hipro products in EU and US markets

Regulatory press release12/16/2025, 7:30 AM

Qlife Holding AB: The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established

Press release12/12/2025, 7:30 AM

Qlife Holding AB: Egoo Health powers AI-driven personalized diabetes management in China

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.